BALTIMORE, Jan. 18 /PRNewswire/ -- Alba Therapeutics Corporation today announced the appointment of Wendy Perrow, as Vice President, Marketing and Alliance Management. In this role, Ms. Perrow will be responsible for leading Alba's marketing development strategy and program execution through product approval and commercialization. Ms. Perrow will also serve as a member of Alba's executive management leadership team.
"We are very pleased to announce that Ms. Perrow is joining Alba in this critical leadership role. Wendy is an accomplished executive with extensive experience in pharmaceutical marketing including both US and global product launches and programs to increase brand use and awareness," said Blake Paterson, M.D., Alba's Chief Executive Officer. "Her leadership in our brand creation and marketing efforts, and management of our corporate alliances will be essential for our success in developing AT-1001 (larazotide acetate) as the first drug for celiac disease," added Dr. Paterson.
"Alba is focused on discovering and commercializing novel therapies for patients with serious autoimmune and inflammatory conditions. It is wonderful to join this innovative organization that is dedicated to bringing new medicines to patients who need them and help change the course of disease," said Ms. Perrow.
Prior to joining Alba, Ms. Perrow held senior executive marketing positions with private and public pharmaceutical companies. From 2004 to 2007, Ms. Perrow was Vice President of Marketing for Sigma-Tau Pharmaceuticals, Inc., a company focused on creating novel therapies for the unmet needs of patients with rare diseases. Her experience ranges from oncology, bone marrow transplant, metabolic disorders, and renal disease. From 1989 to 2003, Ms. Perrow was at Merck and Co., Inc. in the areas of global marketing and U.S. marketing in the areas of Anti-Hypertensives, Vaccines, Cholesterol, and GI. At Merck, she held positions in marketing promotion, international business research analysis, training, and sales. Ms. Perrow began her career in a division of Johnson & Johnson. A skilled marketer, she has led U.S. and global initiatives for leading products that have significantly increased brand awareness and has launched medicines for unmet medical needs.
Ms. Perrow holds a bachelors degree from Eastern Illinois University and a Masters of Business Administration degree in finance and marketing from Duke University - The Fuqua School of Business.
Alba Therapeutics Corporation is a privately held, clinical-stage
biopharmaceutical company based in Baltimore, Maryland. Alba is dedicated
to the development and commercialization of disease-modifying therapeutics
to treat autoimmune and inflammatory diseases, drug delivery agents and
mucosal vaccine adjuvants by exploiting its technology to regulate the
assembly and disassembly of tight junctions in cell barriers throughout the
body. Alba's lead compound, AT-1001 (Larazotide acetate), is targeted
toward the treatment of Celiac Disease, Inflammatory Bowel Disease and Type
Contact: Dr. Bernard McDonald
|SOURCE Alba Therapeutics Corporation|
Copyright©2008 PR Newswire.
All rights reserved